Pacific View Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pacific View Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,216	Closed	-$394K	–	30
2019 Q2	$394K	Buy	6,216 +1,634	+36%	+$104K	0.43%	46
2019 Q1	$319K	Buy	+4,582	New	+$262K	0.33%	48
2018 Q4	–	Sell	-3,526	Closed	-$269K	–	77
2018 Q3	$269K	Sell	3,526 -96	-3%	-$7.81K	0.21%	80
2018 Q2	$279K	Buy	+3,622	New	+$234K	0.22%	87
2018 Q1	–	Sell	-6,276	Closed	-$292K	–	118
2017 Q4	$292K	Buy	+6,276	New	+$308K	0.19%	107

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pacific View Asset Management's RARE Position: Q3 2019 in Review

Pacific View Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2019, closing a stake of 6,216 shares — an estimated $394K sold.

Pacific View Asset Management first reported a position in RARE in Q4 2017 and held it in 5 quarters. The position peaked at $394K in Q2 2019. 172 funds tracked by Wall St. Rank hold RARE as of Q3 2019.

Pacific View Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2019 after selling out during the quarter.
Pacific View Asset Management sold 6,216 Ultragenyx Pharmaceutical shares in Q3 2019, an estimated $394K.
Pacific View Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 5 quarters.
Pacific View Asset Management's Ultragenyx Pharmaceutical position peaked at $394K in Q2 2019.
172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2019.

Based on Pacific View Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.